Informed Consent for Retatrutide: What Your Documentation Must Cover to Be Legally Defensible

Informed consent for an investigational compound is not the same as a standard procedure consent form. When a patient is receiving a compound that has not been FDA-approved for any indication, the consent process carries a higher legal and ethical standard. For retatrutide specifically, your consent documentation must cover a defined set of elements to be legally defensible — and a generic form will not meet that standard.

The federal regulations governing human subjects research (45 CFR 46 and 21 CFR 50) establish the minimum required elements of informed consent for research involving investigational compounds. These are not suggestions. They are the legal standard against which your consent process will be evaluated if your practice is ever investigated by a state medical board, sued by a patient, or audited by a regulatory body.

The required elements include:

1. A statement that the study involves research The consent document must explicitly state that the patient is participating in a research study and that the compound being administered is investigational — meaning it has not been approved by the FDA for any indication.

2. A description of the procedures The consent must describe what will be administered, at what dose, by what route, and on what schedule. It must also describe any procedures that are experimental versus standard of care.

3. A description of foreseeable risks and discomforts For retatrutide, this includes the known risks from the TRIUMPH trial data (nausea, vomiting, diarrhea, injection site reactions, potential thyroid effects) as well as the unknown risks associated with long-term use and the investigational nature of the compound.

4. A description of expected benefits The consent must describe the potential benefits to the patient — or, if there are no direct benefits, a statement to that effect. It must also describe any benefits to others or to science that may reasonably be expected.

5. A disclosure of alternative treatments The consent must disclose the alternatives to participation, including FDA-approved treatments for the same indication. For weight management, this means disclosing semaglutide, tirzepatide, and other approved options.

6. A statement about confidentiality The consent must describe how patient data will be maintained and who will have access to it.

7. Contact information for questions The consent must provide contact information for the IRB and for the principal investigator, so patients know who to contact with questions or concerns.

8. A statement that participation is voluntary The consent must explicitly state that participation is voluntary, that the patient may withdraw at any time without penalty, and that refusal to participate will not affect their access to other care.

A standard procedure consent form — the kind used for routine clinical procedures — does not cover these elements. It typically addresses the procedure itself, the risks of the procedure, and the patient's agreement to proceed. It does not address the investigational nature of the compound, the research context, the IRB oversight structure, or the patient's rights as a research subject.

Using a generic consent form for retatrutide administration is not a minor documentation gap. It is a fundamental failure to meet the legal standard for informed consent in research. If a patient later claims they did not understand they were receiving an investigational compound, a generic consent form provides no protection.

Under an IRB protocol, your consent document must be reviewed and approved by the IRB before you use it. The IRB will evaluate whether the document meets the federal requirements, whether the language is appropriate for your patient population, and whether the risks and benefits are accurately described.

This review process is not a formality. IRBs regularly require revisions to consent documents before approving them. The review process is designed to protect patients — and, by extension, to protect your practice from the liability that comes with inadequate consent.

If you are establishing an IRB protocol for retatrutide, work with healthcare counsel to develop your consent document before submitting it to the IRB. A consent document that has been reviewed by qualified legal counsel and then approved by the IRB is the strongest possible documentation of a compliant consent process.

Maintain signed consent forms in each patient's record. Document the consent conversation — not just the signed form, but a note in the chart indicating that the consent process occurred, that the patient had the opportunity to ask questions, and that they agreed to participate voluntarily.

Review your consent document periodically and update it as new data becomes available from the TRIUMPH trials or other research. An outdated consent document that does not reflect current risk information is a liability.